Ibtissam Marchiq
Overview
Explore the profile of Ibtissam Marchiq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mangelinck A, Molitor E, Marchiq I, Alaoui L, Bouaziz M, Andrade-Pereira R, et al.
PLoS One
. 2024 Dec;
19(12):e0315980.
PMID: 39729479
Improving the selectivity and effectiveness of drugs represents a crucial issue for future therapeutic developments in immuno-oncology. Traditional bulk transcriptomics faces limitations in this context for the early phase of...
2.
Dupouy S, Marchiq I, Derippe T, Almena-Carrasco M, Jozwik A, Fouliard S, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1520-1531.
PMID: 36970059
Background: UCART19 is an "off-the-shelf" genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells. Methods: UCART19 was administered to 25 adult patients with relapsed or...
3.
Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, et al.
Cancer Res Commun
. 2023 Mar;
2(11):1532-1544.
PMID: 36970053
Significance: A mathematical mechanistic pharmacokinetic/pharmacodynamic model supports and captures quantitatively the beneficial impact of lymphodepleting patients before the infusion of an allogeneic CAR-T cell product. Mediation through IL-7 increase and...
4.
Benjamin R, Jain N, Maus M, Boissel N, Graham C, Jozwik A, et al.
Lancet Haematol
. 2022 Oct;
9(11):e833-e843.
PMID: 36228643
Background: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors...
5.
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577501
Immunotherapy with gene engineered CAR and TCR transgenic T-cells is a transformative treatment in cancer medicine. There is a rich pipeline with target antigens and sophisticated technologies that will enable...
6.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, et al.
J Immunother Cancer
. 2022 May;
10(5).
PMID: 35577500
Despite promising clinical results in a small subset of malignancies, therapies based on engineered chimeric antigen receptor and T-cell receptor T cells are associated with serious adverse events, including cytokine...
7.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G, et al.
Lancet
. 2020 Dec;
396(10266):1885-1894.
PMID: 33308471
Background: Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical use, thereby broadening access and applicability....
8.
Sun X, Berger R, Heinrich P, Marchiq I, Pouyssegur J, Renner K, et al.
Metabolites
. 2020 Jul;
10(7).
PMID: 32709039
Glutathione (GSH) and glutathione disulfide (GSSG) are commonly used to assess the oxidative status of a biological system. Various protocols are available for the analysis of GSH and GSSG in...
9.
Zdralevic M, Marchiq I, de Padua M, Parks S, Pouyssegur J
Front Oncol
. 2018 Jan;
7:313.
PMID: 29326883
Research on cancer metabolism has recently re-surfaced as a major focal point in cancer field with a reprogrammed metabolism no longer being considered as a mere consequence of oncogenic transformation,...
10.
Zdralevic M, Vucetic M, Daher B, Marchiq I, Parks S, Pouyssegur J
Adv Biol Regul
. 2018 Jan;
68:55-63.
PMID: 29306548
The evolution of life from extreme hypoxic environments to an oxygen-rich atmosphere has progressively selected for successful metabolic, enzymatic and bioenergetic networks through which a myriad of organisms survive the...